Fig. 6

Relation between TGM2 and tumor immunosuppression in PDAC. a IHC analysis of TGM2 with our tissue microarray (n = 97). The scale bars were shown as indicated: 100 μm and 20 μm. b Survival analysis of TGM2 with tissue microarray data (p = 0.015). c, d Distribution of high- and low-TGM2 group across the three immune subtypes showed as percentage and number. e, f Immune cell composition of high- and low-TGM2 groups. g Enrichment comparison of M2 type macrophages (p = 0.014), Tregs (p = 0.068), pro-B cells (p = 0.00052) and memory B cells (p = 3.7e−06) between high- and low-TGM2 groups. h Comparison of IMs expression between high- and low-TGM2 groups: row is for the immunomodulators and column is for the gene expression value. (CD274, p = 1.0e−14; CD276, p = 1.1e−10; CTLA4, p = 5.6e−07; CX3CL1, p = 1.6e−06; EDNRB, p = 3.8e−06; HAVCR2, p = 4.3e−10; LAG3, p = 0.0046; PDCD1, p = 0.0121; TGFB1, p = 1.2e−12; TIGIT, p = 6.5e−06; TLR4, p = 3.8e−08; VTCN1, p = 0.0585). i Survival analysis of CD276 expression in high-TGM2 group (top) and VTCN1 expression in low-TGM2 group (bottom)